Pharma BD Deal Intelligence
Novartis paid up to $3.5B for Chinook Therapeutics to acquire atrasentan and zigakibart for IgA nephropathy—a kidney disease with millions of patients and no approved disease-modifying therapy at the time. The deal positioned Novartis as the frontrunner in renal inflammation.
Novartis Vanrafia (atrasentan) Phase III ALIGN final data support slowing of kidney function decline in IgA nephropathy: eGFR difference vs placebo…
Novartis finalized the Chinook Therapeutics acquisition in a deal worth up to $3.5 billion, adding two Phase 3 assets for IgA nephropathy to significantly…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Novartis acquired Chinook Therapeutics for up to $3.5 billion ($40.00 per share upfront plus $4.00 per share contingent value right), gaining atrasentan and zigakibart (BION-1301), two late-stage assets for IgA nephropathy (IgAN) and other kidney diseases.
130K US cases/yr · $3M 2030 IgAN market projected
IgA nephropathy (IgAN, Berger's disease) is the most common primary glomerulonephritis worldwide and is characterized by mesangial deposition of galactose-deficient IgA1 immune complexes, mesangial proliferation, and progressive glomerular injury. It typically presents in the second through fourth decades of life with episodic gross hematuria (often following mucosal infection) or incidentally detected microscopic hematuria with proteinuria; hypertension and reduced estimated GFR develop as disease progresses. Without effective treatment, roughly 20-40% of patients progress to kidney failure within 10-20 years of diagnosis, with proteinuria above 1 g/day, reduced eGFR, and hypertension as principal risk factors. Standard management emphasizes optimized renin-angiotensin system blockade and blood-pressure control, with newer disease-modifying agents (targeted-release budesonide, endothelin receptor antagonists, complement inhibitors) added for patients at high risk of progression.
VANRAFIA (atrasentan) launched April 2025 as a leading IgAN therapy. Tarpeyo (budesonide), iptacopan (Fabhalta), and sparsentan (Filspari) also compete. Nephrology adoption, proteinuria endpoints, and ESRD delay messaging are central commercial battlegrounds.
Novartis completed $3.5B acquisition of Chinook Therapeutics ($40/share + $4 CVR), gaining atrasentan for IgA nephropathy and zigakibart for kidney diseases.
Atrasentan Phase 3 demonstrated 36.1% proteinuria reduction vs placebo at 36 weeks in IgA nephropathy. Published in NEJM, validating acquisition thesis.
FDA granted accelerated approval to Vanrafia for IgA nephropathy, the first selective endothelin A receptor antagonist for this indication.
On Feb 13, 2026 Novartis reported final Phase III ALIGN eGFR data for Vanrafia (atrasentan): eGFR difference vs placebo of +2.39 mL/min/1.73m2 at Week 136 (4 weeks off-treatment; 2-sided p=0.057) and +2.59 at Week 132 (study end), supporting slowed kidney-function decline in IgA nephropathy. Novartis plans to file for traditional FDA approval later in 2026, converting the April 2025 accelerated approval. Reinforces the acquisition thesis.
Atrasentan progressed from acquisition to FDA approval (Vanrafia) in under 2 years. First-in-class nephrology drug with blockbuster potential validates $3.5B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Chinook Therapeutics Inc. (this deal) | 2023 | $3.5B | 78 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2023 deals · Novartis AG deals · Nephrology deals